Fungal pathogens are using several mechanisms to circumvent the inhibitory actions of antifungal drugs. The variety of these mechanisms was revealed in recent years by several laboratories with molecular approaches. Besides the identification of genes involved in antifungal drug resistance and the discovery of alternative pathways of resistance (i.e. biofilm formation), novel concepts in the understanding of the survival of fungal pathogen in the presence of antifungal drug (antifungal tolerance) have emerged.
Introduction
Several classes of antifungal drugs are used today to treat fungal infections in humans. Depending on their antifungal properties, these drugs are used in specific clinical situations and for specific fungal species (see Table 1 for further details). The exposure of fungal pathogens to antifungal drugs has different consequences for their metabolism. First, cells can try to overcome the growth inhibitory action of antifungals by the development of various resistance mechanisms. These mechanisms will allow the growth of cells at a higher drug concentration than is the case for normal susceptible cells. Secondly, when the antifungal drug has reached a concentration resulting in growth inhibition, cells can mobilize factors determining if a given agent will be either fungistatic or fungicidal. This property is referred as to antifungal drug tolerance. This short review will lay emphasis on the current understanding of resistance and tolerance mechanisms to antifungal agents.
Established resistance mechanisms to antifungal agents
Resistance to antifungal drugs, which is understood as an increase in minimal inhibition concentration (MIC) as compared to values measured in reference susceptible organisms, has been reported in clinical situations for three classes of antifungal drugs: the polyenes, pyrimidine analogues (5-fluorocytosine) and the azoles (Sanglard & Odds, 2002) . For other classes almost no cases have yet been documented until now. Table 1 summarizes the occurrence of resistance to several antifungal drugs among clinical isolates. The vast majority of clinical cases of antifungal resistance have been reported in their vast majority for the class of azoles. Acquisition of azole resistance in several fungal pathogens has probably been favoured by the repeated use of azoles (especially fluconazole) in treatments of HIV + patients with mucosal fungal infections in the period preceding the introduction of highly active antiretroviral therapy. Acquisition of azole resistance in fungal species has been observed mostly in Candida species including, with decreasing importance, C. albicans, C. glabrata, C. dubliniensis, C. tropicalis and, less frequently, in Cryptococcus neoformans in cases of meningitis (Kontoyiannis & Lewis, 2002) . Azole resistance in systemic fungal infections of severely immuno-compromised patients is much less frequent and has been described mainly for C. albicans (Marr et al., 1997) . Acquisition of azole resistance in filamentous fungi such as Aspergillus fumigatus causing life-threatening invasive diseases has also been observed in few cases in these patients after treatment with itraconazole (Warnock et al., 1999) . Mechanisms of azole resistance have been the most extensively investigated in the recent years, since a high number of isolates has been available to research laboratories. These mechanisms involve: -Alteration of the cytochrome P450 Erg11protein:
Erg11p is responsible for the demethylation of lanosterol and is an important enzyme of ergosterol biosynthesis. Several mutations in Erg11 alleles of azole-resistant Candida species have now been reported and are responsible for a decrease of affinity between azoles and the mutated Erg11p variants ). -Alteration of antifungal transport by enhanced efflux. In azole-resistant yeasts, genes encode two classes of drug efflux pumps in the cell membrane (ATP Binding Cassette (ABC)-transporters and Major Facilitators) are upregulated as compared to the corresponding most azole-susceptible species. Among ABC-transporters genes, CDR1 (Candida Drug Resistance 1) and CDR2 in C. albicans (Sanglard et al., 1997; Sanglard et al., 1995) , CdCDR1 in C. dubliniensis (Moran et al., 1998) , a CDR1 homologue in C. tropicalis (Barchiesi et al., 2000) , CgCDR1 and CgCDR2 in C. glabrata Sanglard et al., 1999) and CnDR in C. neoformans (Posteraro et al., 2003) have been identified as ABC-transporter genes upregulated in azole-resistant isolates. Among Major Facilitators, CaMDR1 (for Multidrug Resistance 1 and also previously known as BEN r for Benomyl resistance) is up-regulated in some C. albicans azoleresistant yeast clinical isolates and several CaMDR1-like genes are also up-regulated in other Candida species such as C. dubliniensis (Wirsching et al., 2000; Wirsching et al., 2001) or C. tropicalis C. tropicalis (Barchiesi et al., 2000) . -Alterations in specific steps of the ergosterol biosynthesis pathway. Some steps of this pathway can be blocked by the occurrence of mutations of specific genes. The result of such alterations is the absence of synthesis of toxic sterol intermediate metabolites but also the absence of ergosterol. This type of alteration is very unfrequent in yeast clinical isolates. In some studies investigating resistance mechanisms to azoles in clinical isolates, sequential isolates with stepwise increase in azole resistance, as measured by susceptibility testing, were available from patients treated with these compounds. Along with the molecular analysis of resistance mechanisms, it became clear that the stepwise increase could be explained by sequential acquisition of mechanisms. Several example have been reported documenting the multifactorial basis of azole resistance in clinical isolates (Perea et al., 2001; White, 1997a; White, 1997b) .
Novel mechanisms of azole resistance
As mentioned above, azole resistance can be correlated with either the upregulation of ABC-transporter genes or Major Facilitator genes. In azole-resistant isolates however, other genes can be co-regulated with these transporters and might also be involved in azole resistance. Microarray experiments, with their ability to examine collections of genes differentially expressed in a genome, represent an attractive tool to identify clusters of genes co-regulated between azole-susceptible and azoleresistant isolates. The expression of co-regulated genes might be controlled by common regulatory circuits converging on the promoters of similar regulatory sequences in these genes. Consistent with this hypothesis, the upregulation of the ABC-transporter genes CDR1 and CDR2 is mediated by a common regulatory element (so called DRE, for Drug Responsive Element) situated in each promoter of these genes (De Micheli et al., 2002) . In a study published by Cowen et al. (2002) , the expression profiles of individual C. albicans isolates with reduced azole susceptibility were investigated, each of which was either upregulating CDR1/CDR2 or CaMDR1. Interestingly, in an isolate upregulating CDR2, other upregulated genes were found and, under them, three (YPL88 (LPG20), YOR49, YLR63) contained in their promoter a consensus for a DRE, the presence of which is necessary for CDR1 and CDR2 upregulation. In the other isolates upregulating CaMDR1, several genes involved in oxidative stress response were also upregulated, thus suggesting that the oxidative stress pathway is contributing to CaMDR1 upregulation. It is likely that in the future additional microarray experiments will be reported using other azole-resistant isolates as tester strains for expression profile analysis. These analyses will be helpful not only because they might cluster genes under the control of specific regulatory pathways, but also because they could reveal still unmasked azole resistance mechanisms.
Besides the main azole resistance mechanisms described above, alternative pathways for the acquisition of resistance can be used by fungi. An interesting alternative for developing azole resistance has been recently described. It uses the ability of fungal pathogens to build biofilms on synthetic or natural surfaces. Biofilms are organized as a dense network of differentiated cells onto which a layer of extracellular matrix can form. Biofilms can constitute a physical barrier for the efficient penetration of antifungals, which could explain that cells embeded in these structures can become recalcitrant to their activity. Measurement of drug susceptibilities in biofilms of C. albicans or C. dubliniensis yielded high MIC values for azoles and amphotericin B as compared to planktonic cells (Chandra et al., 2001; Ramage et al., 2001) . As reported in C. albicans, the expression of genes involved in azole resistance (i.e. multidrug transporter genes) can also be altered in biofilms and may participate in the relatively high azole resistance measured in the cell population of these dense structures (Ramage et al., 2002) .
Mechanisms of antifungal tolerance
Some important antifungal agents in use (fluconazole, itraconazole) have a fungistatic activity against C. albicans, while other compounds have strong (eg. amphotericin B) or moderate (eg. caspofungin) fungicidal activities in C. albicans. The fungistatic nature of azoles limits the efficacy of these substances especially in patients with deep immuno-suppression, since the immune system participates actively with azoles in the elimination of C. albicans from infected sites. Recently, a screening of different types of drugs encountered in medical practice able to potentiate the activity of azoles was undertaken. Among these different drugs, cyclosporin A was found to act in synergism with fluconazole and converted in its vitro fungistatic antifungal effect into a potent fungicidal drug (Marchetti et al., 2000b) . This conversion into a fungicidal agent is due to a loss of tolerance. Tolerance to a given drug is generally defined as the capacity of an organism to survive in the presence of a drug at growth-inhibiting concentrations. The impact of the loss of fluconazole tolerance on drug efficacy has been tested in a rat model of endocarditis due to C. albicans infection (Marchetti et al., 2000a) . The results of animal experiments confirmed those observed in vitro. The combination of fluconazole with cyclosporin A greatly increased the efficacy of fluconazole treatment and reduced fungal load to undetectable levels in infected organs. The molecular mechanisms of cyclosporin A on fluconazole tolerance in C. albicans is thought to be exerted at the level of the cyclophilin-cyclosporin A complex, which inhibits calcineurin functions. (See also Fig 1) Calcineurin is a protein phosphatase conserved among eukaryotes which is activated by a calcium-dependent pathway (Rusnak & Mertz, 2000) . Recent studies report that calcineurin is essential for survival of C. albicans exposed to different environmental stresses and among them, exposure to antifungal agents is of relevance for medical mycologists (Cruz et al., 2002; Sanglard et al., 2003) . The exact mechanisms by which calcineurin protect C. albicans from being killed in the presence of antifungal drugs remain to be elucidated. Moreover, calcineurin has several other functions in the maintenance of cell wall integrity and plays a critical role in the virulence of C. albicans . Calcineurin is also involved in the survival of other fungal pathogens (i.e. C. krusei or C. glabrata) in the presence of antifungal drugs (Bonilla et al., 2002; Cruz et al., 2002) . Inhibition of calcineurin could therefore be utilized in the future for increasing the efficacy of specific antifungal drugs not only by interfering in their tolerance but also in the virulence of fungal species.
Conclusions
Studies on resistance and tolerance mechanisms to antifungal drugs have delivered the different resources utilized by simple microorganisms to circumvent the effect of growth inhibitory substances. Several basic biological processes which emerged from these studies will continue to be investigated and can be used for the purpose of new antifungal drug screening. Alternative pathways of antifungal resistance as observed in biofilm formation deserve research development. Genome-wide expression profiling will give the unique opportunity to obtain a comprehensive analysis of changes in gene expression in several clinical yeast isolates acquiring antifungal drug resistance over time, which until now, has been limited to a restricted number of genes and thus led to the description of a limited number of resistance mechanisms. 
